Pfizer's RSV vaccine was 90% effective at preventing the most severe outcomes in the first-ever vaccination season, the ...

Amicus Therapeutics resolved a patent dispute with Teva on Thursday, allowing Teva to launch a generic version of its Fabry ...

Following a nearly unanimous adcomm against Alfasigma and Intercept Pharmaceuticals’ rare liver disease drug Ocaliva, the FDA ...

Amylyx is trying to move forward with its effort to turn its former ALS drug into a treatment for other conditions, and data ...

Josh Bilenker and Jeff Engelman's secretive startup Treeline Biosciences has another $421 million, according to a new SEC ...

Shape Therapeutics CEO Francois Vigneault has departed the RNA gene therapy startup, and chief scientific officer David Huss ...

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and ...

Merck KGaA said its doors are open for more M&A, particularly for its manufacturing business, as the company tempers sales ...

BenevolentAI's CEO Joerg Moeller is stepping down effective immediately, the London biotech said Thursday, in the latest ...

Avadel Pharmaceuticals said its once-nightly narcolepsy drug Lumryz can now be used to treat children older than 7 years of ...

Plus, news about Kezar Life Sciences and Concentra Biosciences: Viatris, Lexicon Pharmaceuticals sign licensing deal for cardio drug: Per the agreement, Viatris will pay $25 million ...

Australia’s regulatory agency rejected Biogen and Eisai’s Alzheimer’s drug Leqembi, noting that the drug's efficacy doesn't ...